OXiGENE Closes Enrollment of ZYBRESTAT Phase 2 Ovarian Cancer Trial

OXiGENE, Inc. (Nasdaq: OXGN ), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that enrollment has been completed in a randomized Phase 2 clinical trial testing the combination of ZYBRESTAT® (fosbretabulin; CA-4P) plus bevacizumab to treat patients with advanced ovarian cancer. This trial, GOG-0186I, is being conducted by the Gynecologic Oncology Group